⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BDRX News
Biodexa Pharmaceuticals plc American Depositary Shs
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
globenewswire.com
BDRX
Biodexa Announces Pricing of $10 Million Public Offering
globenewswire.com
BDRX
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
globenewswire.com
BDRX
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
globenewswire.com
BDRX
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
globenewswire.com
BDRX
Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025
globenewswire.com
BDRX
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled
accessnewswire.com
BDRX